PARP1 and ovarian cancer: The finding that HRD contributes to approximately 50% of HGSOCs provided a rationale for using cytotoxic platinum-based chemotherapy and exploring the activity of poly (ADPribose) polymerase (PARP) inhibitors in HGSOC (7).Approximately 70% of ovarian cancer patients are diagnosed at an advanced stage, and about 80% of those with advanced stage experience recurrence within 3 years after chemotherapy remission.